米佐利滨治疗IgG4相关病的疗效与安全性:回顾性队列研究
该回顾性队列研究纳入日本东京圣路加国际医院免疫风湿中心的IgG4相关病患者,比较米佐利滨(MZR)组与对照组(单用糖皮质激素或其他免疫抑制剂)的疾病转归。结果显示,MZR在多器官受累患者中显著减少疾病恶化,并显示激素节约效应,但总体人群未见显著差异。
要点
- MZR组多器官受累(≥3个器官)比例显著高于对照组(71.4% vs 31.0%,P=0.021)。
- Kaplan-Meier分析显示MZR在多器官受累患者中显著减少恶化(P<0.001),总体无显著差异(P=0.42)。
- MZR使用与恶化的调整风险比为0.34(95%CI 0.12-1.01;P=0.052),多器官受累为3.51(95%CI 1.29-9.51;P=0.014)。
核心结论
- MZR可减少多器官受累的IgG4相关病患者的疾病恶化,并显示激素节约效应,可能作为治疗选择。
研究设计与样本
- 回顾性队列研究,纳入日本东京圣路加国际医院免疫风湿中心的IgG4相关病患者,MZR组14例,对照组29例。
主要发现
- MZR组多器官受累(≥3个器官)比例显著高于对照组(10例(71.4%) vs 9例(31.0%),P=0.021)。
- Kaplan-Meier分析显示多器官受累患者中MZR显著减少恶化(P<0.001),总体人群无显著差异(P=0.42)。
- MZR使用与恶化的调整风险比为0.34(95%CI 0.12-1.01;P=0.052),多器官受累为3.51(95%CI 1.29-9.51;P=0.014)。
- MZR组累积糖皮质激素剂量(mg/年,四分位距) tended to be lower [1448(1003-1642) vs 2179(1264-3425);P=0.09]。
临床怎么用
- 对于多器官受累的IgG4相关病患者,可考虑使用MZR以减少疾病恶化和节约激素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with IgG4-related disease (IgG4RD) usually require steroid-sparing agents due to relapse with tapering glucocorticoids (GC). We aimed to determine the efficacy and safety of mizoribine (MZR) among IgG4RD patients. METHODS: We retrospectively reviewed records of IgG4RD patients at Immuno-Rheumatology Center in St. Luke's International Hospital, Tokyo, Japan. Patients treated with MZR were classified into the MZR group, and those treated with GC alone or with other immunosuppressants were included in the control group. Disease exacerbation, GC dose, IgG-IgG4 titre and adverse events were evaluated using univariate analyses, including the Kaplan-Meier method. The Cox proportional hazard model was used to evaluate risk factors for disease exacerbation. RESULTS: A total of 14 and 29 cases were included in the MZR and control group. Multiple organ involvement (three or more organs) was significantly more frequent in the MZR group [10 (71.4%) vs 9 (31.0%), P= 0.021]. Kaplan-Meier analysis revealed a significant reduction inexacerbation in patients with multiple organ involvement (P< 0.001) but not in total (P= 0.42). The adjusted hazard ratios of MZR use and multiple organ involvement for exacerbation were 0.34 (95%CI 0.12-1.01; P = 0.052) and 3.51 (95%CI 1.29-9.51; P= 0.014). The cumulative GC dose (mg per year, interquartile range) tended to be lower in the MZR group [1448 (1003-1642) vs 2179 (1264-3425); P= 0.09]. CONCLUSION: MZR decreased disease exacerbation among IgG4RD patients with multi-organ involvement and showed a steroid-sparing effect. MZR could be a treatment option for IgG4RD.
引用
- Fukui S, Kawaai S, Nakai T, et al. Effectiveness and safety of mizoribine for the treatment of IgG4-related disease: a retrospective cohort study. Rheumatology (Oxford). 2021. PMID: 33723568. doi:10.1093/rheumatology/keab235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。